Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
84 hedge funds and large institutions have $216M invested in Bellicum Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 19 reducing their positions, and 33 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 96 → 84 (-12)
18% less capital invested
Capital invested by funds: $263M → $216M (-$47M)
36% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 33
86% less call options, than puts
Call options by funds: $354K | Put options by funds: $2.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.59M |
| 2 |
JP Morgan Chase
New York
|
+$2.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.8M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$1.21M |
| 5 |
Goldman Sachs
New York
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$8.04M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.53M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$5.78M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.12M |
| 5 |
QF
QVT Financial
New York
|
-$3.71M |
BLCM Hedge Fund Activity: Q2 2017 in Review
84 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2017, worth a combined $216M — down 18% from $263M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of BLCM and 21 opened new positions — a net loss of 12 holders — while 19 trimmed existing stakes and 39 added.
The largest buyer was BlackRock, adding an estimated $6.59M. The largest seller was Franklin Resources, exiting entirely with an estimated $8.04M sold.
- 84 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2017, down from 96 in Q1 2017.
- Funds reported $216M of Bellicum Pharmaceuticals, Inc. stock for Q2 2017, down 18% quarter-over-quarter.
- 21 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2017 and 33 closed out, a net change of -12 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2017 was BlackRock, an estimated $6.59M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2017 was Franklin Resources, an estimated $8.04M sold.
Based on aggregated 13F filings for Q2 2017.